Serum PCSK9 Levels Distinguish Individuals Who Do Not Respond to High-Dose Statin Therapy with the Expected Reduction in LDL-C

The purpose of the present report was to examine whether proprotein convertase subtilisin/kexin type 9 (PCSK9) levels differ in individuals who do not exhibit expected reductions in low density lipoprotein cholesterol (LDL-C) with statin therapy. Eighteen nonresponder subjects treated with 80 mg ato...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Beth A., Panza, Gregory, Pescatello, Linda S., Chipkin, Stuart, Gipe, Daniel, Shao, Weiping, White, C. Michael, Thompson, Paul D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127223/
https://www.ncbi.nlm.nih.gov/pubmed/25136459
http://dx.doi.org/10.1155/2014/140723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127223/
https://www.ncbi.nlm.nih.gov/pubmed/25136459
http://dx.doi.org/10.1155/2014/140723

Ejemplares similares